Page 108 - Haematologica May 2022

R. Ram et al.
symptoms in four of 12 domains, while there was no change in both overall health perception and overall quality of life. The 3-month questionnaire, when compared to the base-line questionnaire, showed improvement in disability in all five domains, improvement in all cancer/treatment- related symptoms, improvement of emotional symptoms in ten of 12 domains and improvement both overall health perception (mean baseline 3.83 vs. mean 3 months 5.6, F- 6.007, P=0.005) and overall quality of life (mean baseline 3.87 vs. mean 3 months 5.4, F-2.68, P=0.081).
Efficacy
At date of analysis there were 31 patients (76%) alive and 16 patients (39%) in an ongoing CR state. Non-relapse mor-
tality at 1 and 3 months was 0. Expansion of CAR-T cells on day 7 was available in 19 (46%) patients. There was no dif- ference in the CAR-T cell blood levels between elderly and the control group (P=0.145).
PET-CT at 1 month post CAR-T cell infusion demonstrat- ed CR, partial remission (PR) and progressive disease (PD) in 19 (46%), 7 (17 %), and 13 (32%) patients, respectively. In two patients the results of PET-CT are still pending. There was no difference in the overall response rate (ORR) between the elderly and the control group (63% vs. 78%, respectively, P=0.337). Multivariate binary logistic model identified that high LDH prior to admission for CAR-T cell infusion was associated with lower chances of achieving CR state at day 30 post CAR-T cell infusion (OR: -0.8, 95% CI: 0.48-0.97,
Figure 2. Progression-free survival. Progression- free survival after CAR-T infusion of elderly versus young patients with diffuse large cell B-cell lym- phoma.
Figure 3. Overall survival. Overall survival after CAR-T infusion of elderly versus young patients with diffuse large cell B-cell lymphoma.
1116
haematologica | 2022; 107(5)